NOVATO, Calif., Jan. 9, 2020 /PRNewswire/ — Mercaptor Discoveries (Mercaptor), a company developing therapeutic agents active exclusively at the site of injury, announced the advancement of its preclinical program in epilepsy. The program culminates in human trials, beginning in early 2022. A preclinical-stage company, Mercaptor tackled 2019 with all eyes on lead-selection for epilepsy. Their primary candidate […]
